Skip to content

Neuropace, Inc. NPCE Net Investment in Lease

Net Investment in Lease at other companies

LivaNova logo
LivaNovaLIVN
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Inspire Medical Systems logo
Inspire Medical SystemsINSP
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s net investment in lease?
Neuropace, Inc. (NPCE) reported net investment in lease of $9.68M in Q1 2026.
How has Neuropace, Inc.'s net investment in lease changed year-over-year?
Neuropace, Inc.'s net investment in lease decreased by 15.3% year-over-year, from $11.43M to $9.68M.